comparemela.com

StockNews.com upgraded shares of ProQR Therapeutics (NASDAQ:PRQR – Free Report) from a hold rating to a buy rating in a research report sent to investors on Monday morning. A number of other equities analysts also recently weighed in on the company. Raymond James cut their target price on ProQR Therapeutics from $5.00 to $4.00 and […]

Related Keywords

Raymond James ,Tower Research Capital ,Cubist Systematic Strategies ,Belvedere Trading ,Boothbay Fund Management ,Free Report ,Fund Management ,Research Capital ,Financial Markets ,Systematic Strategies ,Get Free Report ,Proqr Therapeutics ,Nasdaq Prqr ,Prqr ,Medical ,Upgrade ,Stocknews Com ,

© 2024 Vimarsana

comparemela.com © 2020. All Rights Reserved.